The Korean Journal of Medicine

  • 제93권2호
  • /
  • Pages.110-132
  • /
  • 2018
  • /
  • 1738-9364(pISSN)
  • /
  • 2289-0769(eISSN)
대한내과학회 (The Korean Association of Internal Medicine)
권호 표지
DOI QR코드

DOI QR Code

2018 대한부정맥학회 심방세동 환자에서 항응고제의 적합한 선택 및 용량 권고안: 특수 상황과 고위험군 환자

2018 KHRS Expert Consensus Recommendation for Oral Anticoagulants Choice and Appropriate Doses: Specific Situation and High Risk Patients

  • 이기홍 (전남대학교병원 순환기내과) ;
  • 정보영 (연세대학교 세브란스병원 순환기내과) ;
  • 이소령 (순천향대학교병원 순환기내과) ;
  • 황유미 (가톨릭대학교 성빈센트병원 순환기내과) ;
  • 박준범 (이화여자대학교병원 순환기내과) ;
  • 백용수 (인하대학교병원 순환기내과) ;
  • 박예민 (가천대학교 길병원 순환기내과) ;
  • 박진규 (한양대학교 서울병원 순환기내과) ;
  • 박환철 (한양대학교 구리병원 순환기내과) ;
  • 박형욱 (전남대학교병원 순환기내과) ;
  • 이영수 (대구가톨릭대학교 의과대학 순환기내과) ;
  • 최기준 (울산대학교 아산병원 순환기내과)
  • Lee, Ki Hong (Department of Cardiology, Chonnam National University Hospital) ;
  • Joung, Boyoung (Division of Cardiology, Department of Internal Medicine, Severance Cardiovascular Hospital, Yonsei University College of Medicine) ;
  • Lee, So-Ryoung (Department of Cardiology, Soon Chun Hyang University Hospital) ;
  • Hwang, You Mi (Department of Cardiology, St.Vincent Hospital, Catholic University) ;
  • Park, Junbeom (Department of Cardiology, Ewha Womans University Medical Center) ;
  • Baek, Yong Soo (Department of Cardiology, Inha University Hospital) ;
  • Park, Yae Min (Department of Cardiology, Gachon Uniersity Gil Medical Center) ;
  • Park, Jin-Kyu (Department of Cardiology, Hanyang University Seoul Hospital) ;
  • Park, Hwan Cheol (Department of Cardiology, Hanyang University Guri Hospital) ;
  • Park, Hyung Wook (Department of Cardiology, Chonnam National University Hospital) ;
  • Lee, Young Soo (Department of Cardiology, Daegu Catholic University College of Medicine) ;
  • Choi, Kee Joon (Department of Cardiology, Asan Medical Center, Ulsan University)
  • 발행 : 2018.04.01
⟨ 이전 논문 다음 논문 ⟩

초록

Oral anticoagulants (OAC) are necessary to prevent thromboembolism in patients with atrial fibrillation (AF). OACs used in Korea are composed of warfarin and non-vitamin K antagonist OAC. Risk stratification and selection of OACs in patients with AF is usually performed by international guidelines for AF management. However, these guidelines do not always reflect the unique characteristics of AF patients in Korea as they were established based on a small portion of the Asian population and, therefore, have limited application to Korean patients. In addition, under certain conditions, the choice of OACs and doses according to the international guidelines are unsuitable for Korean AF patients. Recently, robust clinical data of Korean AF patients have become available. The Korean AF Management Guideline Committee, as part of the Korean Heart Rhythm Society, analyzed all available studies regarding management of AF including those focusing on Korean patients. Expert consensus and guidelines for optimal management of AF patients in Korea were established following systematic reviews and intensive discussions. This article provides the appropriate choice of OACs and dose for management of Korean AF patients with various clinical conditions.

키워드

참고문헌

  1. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-1151. https://doi.org/10.1056/NEJMoa0905561
  2. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883-891. https://doi.org/10.1056/NEJMoa1009638
  3. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365:981-992. https://doi.org/10.1056/NEJMoa1107039
  4. Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013;369:2093-2104. https://doi.org/10.1056/NEJMoa1310907
  5. Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011;364:806-817. https://doi.org/10.1056/NEJMoa1007432
  6. Albers GW, Diener HC, Frison L, et al. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA 2005;293:690-698. https://doi.org/10.1001/jama.293.6.690
  7. Lee WM, Larrey D, Olsson R, et al. Hepatic findings in long-term clinical trials of ximelagatran. Drug Saf 2005;28:351-370. https://doi.org/10.2165/00002018-200528040-00006
  8. Crijns HJ, Van Gelder IC, Van Gilst WH, Hillege H, Gosselink AM, Lie KI. Serial antiarrhythmic drug treatment to maintain sinus rhythm after electrical cardioversion for chronic atrial fibrillation or atrial flutter. Am J Cardiol 1991;68:335-341. https://doi.org/10.1016/0002-9149(91)90828-9
  9. Lip GY, Beevers DG. ABC of atrial fibrillation. History, epidemiology, and importance of atrial fibrillation. BMJ 1995;311:1361-1363. https://doi.org/10.1136/bmj.311.7016.1361
  10. Krahn AD, Manfreda J, Tate RB, Mathewson FA, Cuddy TE. The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. Am J Med 1995;98:476-484. https://doi.org/10.1016/S0002-9343(99)80348-9
  11. Hohnloser SH, Crijns HJ, van Eickels M, et al. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med 2009;360:668-678. https://doi.org/10.1056/NEJMoa0803778
  12. Lee SH, Park SJ, Byeon K, et al. Risk factors between patients with lone and non-lone atrial fibrillation. J Korean Med Sci 2013;28:1174-1180. https://doi.org/10.3346/jkms.2013.28.8.1174
  13. Choi EK, Park JH, Lee JY, et al. Korean Atrial Fibrillation (AF) Network: genetic variants for AF do not predict ablation success. J Am Heart Assoc 2015;4:e002046. https://doi.org/10.1161/JAHA.115.002046
  14. Lee HY, Yang PS, Kim TH, et al. Atrial fibrillation and the risk of myocardial infarction: a nation-wide propensity-matched study. Sci Rep 2017;7:12716. https://doi.org/10.1038/s41598-017-13061-4
  15. Dans AL, Connolly SJ, Wallentin L, et al. Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Trial Clinical Perspective. Circulation 2013;127:634-640. https://doi.org/10.1161/CIRCULATIONAHA.112.115386
  16. Cannon CP, Bhatt DL, Oldgren J, et al. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med 2017;377:1513-1524. https://doi.org/10.1056/NEJMoa1708454
  17. Gibson CM, Mehran R, Bode C, et al. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med 2016;375:2423-2434. https://doi.org/10.1056/NEJMoa1611594
  18. van Walraven C, Hart RG, Singer DE, et al. Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis. JAMA 2002;288:2441-2448. https://doi.org/10.1001/jama.288.19.2441
  19. Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014;383:955-962. https://doi.org/10.1016/S0140-6736(13)62343-0
  20. Graham DJ, Reichman ME, Wernecke M, et al. Cardiovascular, bleeding, and mortality risks in elderly medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. Circulation 2015;131:157-164. https://doi.org/10.1161/CIRCULATIONAHA.114.012061
  21. Lip GY, Windecker S, Huber K, et al. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensSus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS). Eur Heart J 2014;35:3155-3179. https://doi.org/10.1093/eurheartj/ehu298
  22. Griffin WF, Salahuddin T, O'Neal WT, Soliman EZ. Peripheral arterial disease is associated with an increased risk of atrial fibrillation in the elderly. Europace 2016;18:794-798. https://doi.org/10.1093/europace/euv369
  23. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001;285:2370-2375. https://doi.org/10.1001/jama.285.18.2370
  24. O'Neal WT, Efird JT, Nazarian S, Alonso A, Heckbert SR, Soliman EZ. Peripheral arterial disease and risk of atrial fibrillation and stroke: the multi-ethnic study of atherosclerosis. J Am Heart Assoc 2014;3:e001270. https://doi.org/10.1161/JAHA.114.001270
  25. Wasmer K, Unrath M, Kobe J, et al. Atrial fibrillation is a risk marker for worse in-hospital and long-term outcome in patients with peripheral artery disease. Int J Cardiol 2015;199:223-228. https://doi.org/10.1016/j.ijcard.2015.06.094
  26. Winkel TA, Hoeks SE, Schouten O, et al. Prognosis of atrial fibrillation in patients with symptomatic peripheral arterial disease: data from the REduction of Atherothrombosis for Continued Health (REACH) Registry. Eur J Vasc Endovasc Surg 2010;40:9-16. https://doi.org/10.1016/j.ejvs.2010.03.003
  27. Jones WS, Hellkamp AS, Halperin J, et al. Efficacy and safety of rivaroxaban compared with warfarin in patients with peripheral artery disease and non-valvular atrial fibrillation: insights from ROCKET AF. Eur Heart J 2014;35:242-249. https://doi.org/10.1093/eurheartj/eht492
  28. Hu PT, Lopes RD, Stevens SR, et al. Efficacy and safety of apixaban compared with warfarin in patients with atrial fibrillation and peripheral artery disease: insights from the ARISTOTLE trial. J Am Heart Assoc 2017;6:e004699. https://doi.org/10.1161/JAHA.116.004699
  29. Tangelder MJ, Nwachuku CE, Jaff M, et al. A review of antithrombotic therapy and the rationale and design of the randomized edoxaban in patients with peripheral artery disease (ePAD) trial adding edoxaban or clopidogrel to aspirin after femoropopliteal endovascular intervention. J Endovasc Ther 2015;22:261-268. https://doi.org/10.1177/1526602815574687
  30. Valgimigli M, Bueno H, Byrne RA, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2018;39:213-260. https://doi.org/10.1093/eurheartj/ehx419
  31. Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016;37:2893-2962. https://doi.org/10.1093/eurheartj/ehw210
  32. Diener HC, Aisenberg J, Ansell J, et al. Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 1. Eur Heart J 2017;38:852-859.
  33. Onishi H, Yumoto K, Sakata O. Oral biodisposition study of ritodrine after its buccal administration in rats. Curr Drug Deliv 2017;14:634-640.
  34. Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace 2016;18:1609-1678. https://doi.org/10.1093/europace/euw295
  35. Gallagher MM, Hennessy BJ, Edvardsson N, et al. Embolic complications of direct current cardioversion of atrial arrhythmias: association with low intensity of anticoagulation at the time of cardioversion. J Am Coll Cardiol 2002;40:926-933. https://doi.org/10.1016/S0735-1097(02)02052-1
  36. Bjerkelund CJ, Orning OM. The efficacy of anticoagulant therapy in preventing embolism related to D.C. electrical conversion of atrial fibrillation. Am J Cardiol 1969;23:208-216. https://doi.org/10.1016/0002-9149(69)90068-X
  37. Shin DG, Cho I, Hartaigh B, et al. Cardiovascular events of electrical cardioversion under optimal anticoagulation in atrial fibrillation: the multicenter analysis. Yonsei Med J 2015;56:1552-1558. https://doi.org/10.3349/ymj.2015.56.6.1552
  38. Shin DG, Mun HS, Lee HY, et al. The effect of transesophageal echocardiography on the incidence of thromboembolism after electrical cardioversion in atrial fibrillation: A multicenter analysis. Int J Cardiol 2016;202:880-882. https://doi.org/10.1016/j.ijcard.2015.10.037
  39. Nagarakanti R, Ezekowitz MD, Oldgren J, et al. Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. Circulation 2011;123:131-136. https://doi.org/10.1161/CIRCULATIONAHA.110.977546
  40. Flaker G, Lopes RD, Al-Khatib SM, et al. Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation). J Am Coll Cardiol 2014;63:1082-1087. https://doi.org/10.1016/j.jacc.2013.09.062
  41. Piccini JP, Stevens SR, Lokhnygina Y, et al. Outcomes after cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial. J Am Coll Cardiol 2013;61:1998-2006. https://doi.org/10.1016/j.jacc.2013.02.025
  42. Cappato R, Ezekowitz MD, Klein AL, et al. Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation. Eur Heart J 2014;35:3346-3355. https://doi.org/10.1093/eurheartj/ehu367
  43. Goette A, Merino JL, Ezekowitz MD, et al. Edoxaban versus enoxaparin–warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial. Lancet 2016;388:1995-2003. https://doi.org/10.1016/S0140-6736(16)31474-X
  44. Renda G, Zimarino M, Ricci F, et al. Efficacy and safety of non-vitamin K antagonist oral anticoagulants after cardioversion for nonvalvular atrial fibrillation. Am J Med 2016;129:1117-1123.e2. https://doi.org/10.1016/j.amjmed.2016.05.007
  45. Sen P, Kundu A, Sardar P, et al. Outcomes after cardioversion in atrial fibrillation patients treated with non-vitamin K antagonist oral anticoagulants (NOACs): insights from a meta-analysis. Am J Cardiovasc Drugs 2016;16:33-41. https://doi.org/10.1007/s40256-015-0136-1
  46. Briasoulis A, Kottam A, Khan M, Afonso L. Novel oral anticoagulants in patients undergoing cardioversion for atrial fibrillation. J Thromb Thrombolysis 2015;40:139-143. https://doi.org/10.1007/s11239-014-1161-7
  47. Coleman CM, Khalaf S, Mould S, et al. Novel oral anticoagulants for DC cardioversion procedures: utilization and clinical outcomes compared with warfarin. Pacing Clin Electrophysiol 2015;38:731-737. https://doi.org/10.1111/pace.12618
  48. Itainen S, Lehto M, Vasankari T, et al. Non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients undergoing elective cardioversion. Europace 2017 Jul 10 [Epub]. http://dx.doi.org/10.1093/europace/eux116.
  49. Frederiksen AS, Albertsen AE, Christesen AMS, Vinter N, Frost L, Moller DS. Cardioversion of atrial fibrillation in a real-world setting: non-vitamin K antagonist oral anticoagulants ensure a fast and safe strategy compared to warfarin. Europace 2017 Jun 26 [Epub]. http://dx.doi.org/10.1093/europace/eux188.
  50. Chun KJ, Park KM, Park SJ, Kim JS, On YK. Efficacy and transesophageal echocardiographic findings of short- term dabigatran or rivaroxaban therapy for electrical cardioversion in patients with atrial fibrillation. Int J Arrhythm 2015;16:134-140. https://doi.org/10.18501/arrhythmia.2015.023
  51. Cappato R, Calkins H, Chen SA, et al. Updated worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circ Arrhythm Electrophysiol 2010;3:32-38. https://doi.org/10.1161/CIRCEP.109.859116
  52. Scherr D, Sharma K, Dalal D, et al. Incidence and predictors of periprocedural cerebrovascular accident in patients undergoing catheter ablation of atrial fibrillation. J Cardiovasc Electrophysiol 2009;20:1357-1363. https://doi.org/10.1111/j.1540-8167.2009.01540.x
  53. Spragg DD, Dalal D, Cheema A, et al. Complications of catheter ablation for atrial fibrillation: incidence and predictors. J Cardiovasc Electrophysiol 2008;19:627-631. https://doi.org/10.1111/j.1540-8167.2008.01181.x
  54. Di Biase L, Burkhardt JD, Mohanty P, et al. Periprocedural stroke and management of major bleeding complications in patients undergoing catheter ablation of atrial fibrillation: the impact of periprocedural therapeutic international normalized ratio. Circulation 2010;121:2550-2556. https://doi.org/10.1161/CIRCULATIONAHA.109.921320
  55. Santangeli P, Di Biase L, Horton R, et al. Ablation of atrial fibrillation under therapeutic warfarin reduces periprocedural complications: evidence from a meta-analysis. Circ Arrhythm Electrophysiol 2012;5:302-311. https://doi.org/10.1161/CIRCEP.111.964916
  56. Knecht S, Oelschlager C, Duning T, et al. Atrial fibrillation in stroke-free patients is associated with memory impairment and hippocampal atrophy. Eur Heart J 2008;29:2125-2132. https://doi.org/10.1093/eurheartj/ehn341
  57. Haines DE, Stewart MT, Barka ND, et al. Microembolism and catheter ablation II: effects of cerebral microemboli injection in a canine model. Circ Arrhythm Electrophysiol 2013;6:23-30. https://doi.org/10.1161/CIRCEP.112.973461
  58. Di Biase L, Burkhardt D, Santangeli P, et al. Periprocedural Stroke and Bleeding Complications in Patients undergoing Catheter Ablation of Atrial Fibrillation with Different Anticoagulation Management: Results from the (COMPARE) Randomized Trial. Circulation 2014:129:2638-2644. https://doi.org/10.1161/CIRCULATIONAHA.113.006426
  59. Camm AJ, Lip GY, De Caterina R, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrial fibrillation--developed with the special contribution of the European Heart Rhythm Association. Europace 2012;14:1385-1413. https://doi.org/10.1093/europace/eus305
  60. Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014;383:955-962. https://doi.org/10.1016/S0140-6736(13)62343-0
  61. Nagao T, Inden Y, Shimano M, et al. Feasibility and safety of uninterrupted dabigatran therapy in patients undergoing ablation for atrial fibrillation. Intern Med 2015;54:1167-1173. https://doi.org/10.2169/internalmedicine.54.3520
  62. Hohnloser SH, Camm AJ. Safety and efficacy of dabigatran etexilate during catheter ablation of atrial fibrillation: a meta-analysis of the literature. Europace 2013;15:1407-1411. https://doi.org/10.1093/europace/eut241
  63. Eitel C, Koch J, Sommer P, et al. Novel oral anticoagulants in a real-world cohort of patients undergoing catheter ablation of atrial fibrillation. Europace 2013;15:1587-1593. https://doi.org/10.1093/europace/eut128
  64. Lakkireddy D, Reddy YM, Di Biase L, et al. Feasibility and safety of uninterrupted rivaroxaban for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry. J Am Coll Cardiol 2014;63:982-988. https://doi.org/10.1016/j.jacc.2013.11.039
  65. Di Biase L, Lakkireddy D, Trivedi C, et al. Feasibility and safety of uninterrupted periprocedural apixaban administration in patients undergoing radiofrequency catheter ablation for atrial fibrillation: results from a multicenter study. Heart Rhythm 2015;12:1162-1168. https://doi.org/10.1016/j.hrthm.2015.02.028
  66. Kaess BM, Ammar S, Reents T, et al. Comparison of safety of left atrial catheter ablation procedures for atrial arrhythmias under continuous anticoagulation with apixaban versus phenprocoumon. Am J Cardiol 2015;115:47-51. https://doi.org/10.1016/j.amjcard.2014.10.005
  67. Cappato R, Marchlinski F, Hohnloser S; VENTURE-AF Investigators, et al. Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation. Eur Heart J 2015;36:1805-1811. https://doi.org/10.1093/eurheartj/ehv177
  68. Providencia R, Marijon E, Albenque JP, et al. Rivaroxaban and dabigatran in patients undergoing catheter ablation of atrial fibrillation. Europace 2014;16:1137-1144. https://doi.org/10.1093/europace/euu007
  69. Aryal MR, Ukaigwe A, Pandit A, et al. Meta-analysis of efficacy and safety of rivaroxaban compared with warfarin or dabigatran in patients undergoing catheter ablation for atrial fibrillation. Am J Cardiol 2014;114:577-582. https://doi.org/10.1016/j.amjcard.2014.05.038
  70. Wu S, Yang YM, Zhu J, et al. Meta-analysis of efficacy and safety of new oral anticoagulants compared with uninterrupted vitamin K antagonists in patients undergoing catheter ablation for atrial fibrillation. Am J Cardiol 2016;117:926-934. https://doi.org/10.1016/j.amjcard.2015.12.027
  71. Santarpia G, De Rosa S, Polimeni A, et al. Efficacy and safety of non-vitamin k antagonist oral anticoagulants versus vitamin k antagonist oral anticoagulants in patients undergoing radiofrequency catheter ablation of atrial fibrillation: a meta-analysis. PLoS One 2015;10:e0126512. https://doi.org/10.1371/journal.pone.0126512
  72. Calkins H,Willems S, Gerstenfeld EP, et al. Uninterrupted dabigatran versus warfarin for ablation in atrial fibrillation. N Engl J Med 2017;376:1627-1636. https://doi.org/10.1056/NEJMoa1701005
  73. Karasoy D, Gislason GH, Hansen J, et al. Oral anticoagulation therapy after radiofrequency ablation of atrial fibrillation and the risk of thromboembolism and serious bleeding: long-term follow-up in nationwide cohort of Denmark. Eur Heart J 2014;36:307-315.
  74. Themistoclakis S, Corrado A, Marchlinski FE, et al. The risk of thromboembolism and need for oral anticoagulation after successful atrial fibrillation ablation. J Am Coll Cardiol 2010;55:735-743. https://doi.org/10.1016/j.jacc.2009.11.039
  75. Nedios S, Kornej J, Koutalas E, et al. Left atrial appendage morphology and thromboembolic risk after catheter ablation for atrial fibrillation. Heart Rhythm 2014;11:2239-2246. https://doi.org/10.1016/j.hrthm.2014.08.016
  76. Reynolds MR, Gunnarsson CL, Hunter TD, et al. Health outcomes with catheter ablation or antiarrhythmic drug therapy in atrial fibrillation. Circ Cardiovasc Qual Outcomes 2012;5:171-181. https://doi.org/10.1161/CIRCOUTCOMES.111.963108
  77. Gallo C, Battaglia A, Anselmino M, et al. Long-term events following atrial fibrillation rate control or transcatheter ablation: a multicenter observational study. J Cardiovasc Med (Hagerstown) 2016;17:187-193. https://doi.org/10.2459/JCM.0000000000000311
  78. Shin DG, Kim TH, Uhm JS, et al. Early experience of novel oral anticoagulants in catheter ablation for atrial fibrillation: efficacy and safety comparison to warfarin. Yonsei Med J 2016;57:342-349. https://doi.org/10.3349/ymj.2016.57.2.342
  79. Wan Y, Heneghan C, Perera R, et al. Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review. Circ Cardiovasc Qual Outcomes 2008;1:84-91. https://doi.org/10.1161/CIRCOUTCOMES.108.796185
  80. Gallego P, Roldan V, Marin F, et al. Cessation of oral anticoagulation in relation to mortality and the risk of thrombotic events in patients with atrial fibrillation. Thromb Haemost 2013;110:1189-1198. https://doi.org/10.1160/TH13-07-0556
  81. Sjogren V, Grzymala-Lubanski B, Renlund H, et al. Safety and efficacy of well managed warfarin. A report from the Swedish quality register Auricula. Thromb Haemost 2015;113:1370-1377. https://doi.org/10.1160/TH14-10-0859
  82. De Caterina R, Husted S, Wallentin L, et al. Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC working group on thrombosis--task force on anticoagulants in heart disease. Thromb Haemost 2013;110:1087-1107. https://doi.org/10.1160/TH13-06-0443
  83. Gallego P, Roldan V, Marin F, et al. SAMe-TT2R2 score, time in therapeutic range, and outcomes in anticoagulated patients with atrial fibrillation. Am J Med 2014;127:1083-1088. https://doi.org/10.1016/j.amjmed.2014.05.023
  84. Lip GYH, Haguenoer K, Saint-Etienne C, Fauchier L. Relationship of the SAMe-TT2R2 score to poor-quality anticoagulation, stroke, clinically relevant bleeding, and mortality in patients with atrial fibrillation. Chest 2014;146:719-726. https://doi.org/10.1378/chest.13-2976
  85. Apostolakis S, Sullivan RM, Olshansky B, Lip GYH. Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT2R2 score. Chest 2013;144:1555-1563. https://doi.org/10.1378/chest.13-0054
  86. Chao TF, Liu CJ, Wang KL, et al. Using the CHA2DS2-VASc score for refining stroke risk stratification in 'low-risk' Asian patients with atrial fibrillation. J Am Coll Cardiol 2014;64:1658-1665. https://doi.org/10.1016/j.jacc.2014.06.1203
  87. Lip GY, SkjothF, Rasmussen LH, Larsen TB. Oral anticoagulation, aspirin, or no therapy in patients with nonvalvular AF with 0 or 1 stroke risk factor based on the CHA2DS2-VASc score. J Am Coll Cardiol 2015;65:1385-1394. https://doi.org/10.1016/j.jacc.2015.01.044
  88. Nielsen PB, Chao TF. The risks of risk scores for stroke risk assessment in atrial fibrillation. Thromb Haemost 2015;113:1170-1173. https://doi.org/10.1160/TH15-03-0210
  89. Olesen JB, Torp-Pedersen C. Stroke risk in atrial fibrillation: Do we anticoagulate CHADS2 or CHA2DS2-VASc $\geq$1, or higher? Thromb Haemost 2015;113:1165-1169. https://doi.org/10.1160/TH15-02-0154
  90. Kang SH, Choi EK, Han KD, et al. Risk of ischemic stroke in patients with non-valvular atrial fibrillation not receiving oral anticoagulants-Korean nationwide population-based study. Circ J 2017;81:1158-1164. https://doi.org/10.1253/circj.CJ-16-1267
  91. Kim TH, Yang PS, Kim D, et al. CHA2DS2-VASc score for identifying truly low-risk atrial fibrillation for stroke: a Korean nationwide cohort study. Stroke 2017;48:2984-2990. https://doi.org/10.1161/STROKEAHA.117.018551
  92. Kim TH, Yang PS, Uhm JS, et al. CHA2DS2-VASc score (congestive heart failure, hypertension, age >/=75 [doubled], diabetes mellitus, prior stroke or transient ischemic attack [doubled], vascular disease, age 65-74, female) for stroke in asian patients with atrial fibrillation: a Korean Nationwide Sample Cohort Study. Stroke 2017;48:1524-1530. https://doi.org/10.1161/STROKEAHA.117.016926
  93. Breithardt G, Baumgartner H, Berkowitz SD, et al. Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial. Eur Heart J 2014;35:3377-3385. https://doi.org/10.1093/eurheartj/ehu305
  94. Huang D, Anguo L, Yue WS, Yin L, Tse HF, Siu CW. Refinement of ischemic stroke risk in patients with atrial fibrillation and CHA2 DS2 -VASc score of 1. Pacing Clin Electrophysiol 2014;37:1442-1447. https://doi.org/10.1111/pace.12445
  95. Chao TF, LiuCJ, Wang KL, et al. Should atrial fibrillation patients with 1 additional risk factor of the CHA2DS2-VASc score (beyond sex) receive oral anticoagulation? J Am Coll Cardiol 2015;65:635-642. https://doi.org/10.1016/j.jacc.2014.11.046
  96. Lip GY, Skjoth F, Rasmussen LH, Nielsen PB, Larsen TB. Net clinical benefit for oral anticoagulation, aspirin, or no therapy in nonvalvular atrial fibrillation patients with 1 additional risk factor of the CHA2DS2-VASc score (beyond sex). J Am Coll Cardiol 2015;66:488-490. https://doi.org/10.1016/j.jacc.2015.05.044
  97. Lip GY, Lane DA. Modern management of atrial fibrillation requires initial identification of "low-risk" patients using the CHA2DS2-VASc score, and not focusing on "high-risk" prediction. Circ J 2014;78:1843-1845. https://doi.org/10.1253/circj.CJ-14-0584
  98. Lip GY, Lane DA. Stroke prevention in atrial fibrillation: a systematic review. JAMA 2015;313:1950-1962. https://doi.org/10.1001/jama.2015.4369
  99. Fauchier L, Lecoq C, Clementy N, et al. Oral anticoagulation and the risk of stroke or death in patients with atrial fibrillation and one additional stroke risk factor: The Loire Valley atrial fibrillation project. Chest 2016149:960-968. https://doi.org/10.1378/chest.15-1622
  100. Lopes RD, Al-Khatib SM, Wallentin L, et al. Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial. Lancet 2012;380:1749-1758. https://doi.org/10.1016/S0140-6736(12)60986-6
  101. Eikelboom JW, Wallentin L, Connolly SJ, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation 2011;123:2363-2372. https://doi.org/10.1161/CIRCULATIONAHA.110.004747
  102. Eckman MH, Singer DE, Rosand J, Greenberg SM. Moving the tipping point: the decision to anticoagulate patients with atrial fibrillation. Circ Cardiovasc Qual Outcomes 2011;4:14-21. https://doi.org/10.1161/CIRCOUTCOMES.110.958108
  103. Seeger JD, Bykov K, Bartels DB, Huybrechts K, Zint K, Schneeweiss S. Safety and effectiveness of dabigatran and warfarin in routine care of patients with atrial fibrillation. Thromb Haemost 2015;114:1277-1289. https://doi.org/10.1160/TH15-06-0497
  104. Hohnloser SH, Pajitnev D, Pogue J, et al. Incidence of stroke in paroxysmal versus sustained atrial fibrillation in patients taking oral anticoagulation or combined antiplatelet therapy: an ACTIVE W Substudy. J Am Coll Cardiol 2007;50:2156-2161. https://doi.org/10.1016/j.jacc.2007.07.076
  105. Friberg L, Hammar N, Pettersson H, Rosenqvist M. Increased mortality in paroxysmal atrial fibrillation: report from the Stockholm Cohort-Study of Atrial Fibrillation (SCAF). Eur Heart J 2007;28:2346-2353. https://doi.org/10.1093/eurheartj/ehm308
  106. Vanassche T, Lauw MN, Eikelboom JW, et al. Risk of ischaemic stroke according to pattern of atrial fibrillation: analysis of 6563 aspirin-treated patients in ACTIVE-A and AVERROES. Eur Heart J 2015;36:281-287a. https://doi.org/10.1093/eurheartj/ehu307
  107. Steinberg BA, Hellkamp AS, Lokhnygina Y, et al. Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF Trial. Eur Heart J 2015;36:288-296. https://doi.org/10.1093/eurheartj/ehu359
  108. Healey JS, Connolly SJ, Gold MR, et al. Subclinical atrial fibrillation and the risk of stroke. N Engl J Med 2012;366:120-129. https://doi.org/10.1056/NEJMoa1105575
  109. Binici Z, Intzilakis T, Nielsen OW, Kober L, Sajadieh A. Excessive supraventricular ectopic activity and increased risk of atrial fibrillation and stroke. Circulation 2010;121:1904-1911. https://doi.org/10.1161/CIRCULATIONAHA.109.874982
  110. Steffel J, Giugliano R, Braunwald E, et al. Edoxaban vs. warfarin in patients with atrial fibrillation on amiodarone: a subgroup analysis of the ENGAGE AF-TIMI 48 trial. Eur Heart J 2015;36:2239-2245. https://doi.org/10.1093/eurheartj/ehv201
  111. Heidbuchel H, Verhamme P, Alings M, et al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace 2015;17:1467-1507. https://doi.org/10.1093/europace/euv309
  112. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group. Lancet 1993;342:1255-1262.
  113. Diener HC, Connolly SJ, Ezekowitz MD, et al. Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial. Lancet Neurol 2010;9:1157-1163. https://doi.org/10.1016/S1474-4422(10)70274-X
  114. Hankey GJ, Patel MR, Stevens SR, et al. Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF. Lancet Neurol 2012;11:315-322. https://doi.org/10.1016/S1474-4422(12)70042-X
  115. Easton JD, Lopes RD, Bahit MC, et al. Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial. Lancet Neurol 2012;11:503-511. https://doi.org/10.1016/S1474-4422(12)70092-3
  116. Diener HC, Eikelboom J, Connolly SJ, et al. Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a predefined subgroup analysis from AVERROES, a randomised trial. Lancet Neurol 2012;11:225-231. https://doi.org/10.1016/S1474-4422(12)70017-0
  117. Ntaios G, Papavasileiou V, Diener HC, Makaritsis K, Michel P. Nonvitamin-K-antagonist oral anticoagulants in patients with atrial fibrillation and previous stroke or transient ischemic attack: a systematic review and meta-analysis of randomized controlled trials. Stroke 2012;43:3298-3304. https://doi.org/10.1161/STROKEAHA.112.673558
  118. Flaker GC, Gruber M, Connolly SJ, et al. Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials. Am Heart J 2006;152:967-973. https://doi.org/10.1016/j.ahj.2006.06.024
  119. Clemens A, Strack A, Noack H, Konstantinides S, Brueckmann M, Lip GY. Anticoagulant-related gastrointestinal bleeding--could this facilitate early detection of benign or malignant gastrointestinal lesions? Ann Med 2014;46:672-678. https://doi.org/10.3109/07853890.2014.952327
  120. Vaughan Sarrazin MS, Jones M, Mazur A, Chrischilles E, Cram P. Bleeding rates in Veterans Affairs patients with atrial fibrillation who switch from warfarin to dabigatran. Am J Med 2014;127:1179-1185. https://doi.org/10.1016/j.amjmed.2014.07.024
  121. Hernandez I, Baik SH, Pinera A, Zhang Y. Risk of bleeding with dabigatran in atrial fibrillation. JAMA Intern Med 2015;175:18-24. https://doi.org/10.1001/jamainternmed.2014.5398
  122. Abraham NS, Singh S, Alexander GC, et al. Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study. BMJ 2015;350:h1857. https://doi.org/10.1136/bmj.h1857
  123. Chang HY, Zhou M, Tang W, Alexander GC, Singh S. Risk of gastrointestinal bleeding associated with oral anticoagulants: population based retrospective cohort study. BMJ 2015;350:h1585. https://doi.org/10.1136/bmj.h1585
  124. Larsen TB, Gorst-Rasmussen A, Rasmussen LH, Skjoth F, Rosenzweig M, Lip GY. Bleeding events among new starters and switchers to dabigatran compared with warfarin in atrial fibrillation. Am J Med 2014;127:650-656 e655. https://doi.org/10.1016/j.amjmed.2014.01.031
  125. Larsen TB, Rasmussen LH, Skjoth F, et al. Efficacy and safety of dabigatran etexilate and warfarin in "real-world" patients with atrial fibrillation: a prospective nationwide cohort study. J Am Coll Cardiol 2013;61:2264-2273. https://doi.org/10.1016/j.jacc.2013.03.020
  126. Manatsathit W, Al-Hamid H, Leelasinjaroen P, Hashmi U, McCullough PA. Management of gastrointestinal bleeding in patients anticoagulated with dabigatran compared with warfarin: a retrospective, comparative case review. Cardiovasc Diagn Ther 2014;4:224-231.
  127. Chan EW, Lau WC, Leung WK, et al. Prevention of dabigatran-related gastrointestinal bleeding with gastroprotective agents: a population-based study. Gastroenterology 2015;149:586-595.e3. https://doi.org/10.1053/j.gastro.2015.05.002
  128. Goodman SG, Wojdyla DM, Piccini JP, et al. Factors associated with major bleeding events: insights from the ROCKET AF trial (rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation). J Am Coll Cardiol 2014;63:891-900. https://doi.org/10.1016/j.jacc.2013.11.013
  129. Halperin JL, Hankey GJ, Wojdyla DM, et al. Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the rivaroxaban once daily, oral, direct factor xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF). Circulation 2014;130:138-146. https://doi.org/10.1161/CIRCULATIONAHA.113.005008
  130. Piccini JP, Garg J, Patel MR, et al. Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trial. Eur Heart J 2014;35:1873-1880. https://doi.org/10.1093/eurheartj/ehu083
  131. Hori M, Matsumoto M, Tanahashi N, et al. Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation - the J-ROCKET AF study. Circ J 2012;76:2104-2111. https://doi.org/10.1253/circj.CJ-12-0454
  132. Laliberte F, Cloutier M, Nelson WW, et al. Real-world comparative effectiveness and safety of rivaroxaban and warfarin in nonvalvular atrial fibrillation patients. Curr Med Res Opin 2014;30:1317-1325. https://doi.org/10.1185/03007995.2014.907140
  133. Fox KA, Piccini JP, Wojdyla D, et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarinin patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J 2011;32:2387-2394. https://doi.org/10.1093/eurheartj/ehr342
  134. Eikelboom JW, Connolly SJ, Gao P, et al. Stroke risk and efficacy of apixaban in atrial fibrillation patients with moderate chronic kidney disease. J Stroke Cerebrovasc Dis 2012;21:429-435. https://doi.org/10.1016/j.jstrokecerebrovasdis.2012.05.007
  135. Hohnloser SH, Hijazi Z, Thomas L, et al. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J 2012;33:2821-2830. https://doi.org/10.1093/eurheartj/ehs274
  136. Hijazi Z, Hohnloser SH, Oldgren J, et al. Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (randomized evaluation of long-term anticoagulation therapy) trial analysis. Circulation 2014;129:961-970. https://doi.org/10.1161/CIRCULATIONAHA.113.003628
  137. Lee SR, Choi EK, Han KD, Cha MJ, Oh S. Trends in the incidence and prevalence of atrial fibrillation and estimated thromboembolic risk using the CHA2DS2-VASc score in the entire Korean population. Int J Cardiol 2017;236:226-231. https://doi.org/10.1016/j.ijcard.2017.02.039
  138. Olesen JB, Lip GY, Kamper AL, et al. Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med 2012;367:625-635. https://doi.org/10.1056/NEJMoa1105594
  139. Carrero JJ, Evans M, Szummer K, et al. Warfarin, kidney dysfunction, and outcomes following acute myocardial infarction in patients with atrial fibrillation. JAMA 2014;311:919-928. https://doi.org/10.1001/jama.2014.1334
  140. Zimmerman D, Sood MM, Rigatto C, Holden RM, Hiremath S, Clase CM. Systematic review and meta-analysis of incidence, prevalence and outcomes of atrial fibrillation in patients on dialysis. Nephrol Dial Transplant 2012;27:3816-3822. https://doi.org/10.1093/ndt/gfs416
  141. Wizemann V, Tong L, Satayathum S, et al. Atrial fibrillation in hemodialysis patients: clinical features and associations with anticoagulant therapy. Kidney Int 2010;77:1098-1106. https://doi.org/10.1038/ki.2009.477
  142. Chan KE, Lazarus JM, Thadhani R, Hakim RM. Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation. J Am Soc Nephrol 2009;20:2223-2233. https://doi.org/10.1681/ASN.2009030319
  143. Winkelmayer WC, Liu J, Setoguchi S, Choudhry NK. Effectiveness and safety of warfarin initiation in older hemodialysis patients with incident atrial fibrillation. Clin J Am Soc Nephrol 2011;6:2662-2668. https://doi.org/10.2215/CJN.04550511
  144. Schwartzenberg S, Lev EI, Sagie A, Korzets A, Kornowski R. The quandary of oral anticoagulation in patients with atrial fibrillation and chronic kidney disease. Am J Cardiol 2016;117:477-482. https://doi.org/10.1016/j.amjcard.2015.10.065
  145. Shah M, Avgil Tsadok M, Jackevicius CA, et al. Warfarin use and the risk for stroke and bleeding in patients with atrial fibrillation undergoing dialysis. Circulation 2014;129:1196-1203. https://doi.org/10.1161/CIRCULATIONAHA.113.004777
  146. Bonde AN, Lip GY, Kamper AL, et al. Net clinical benefit of antithrombotic therapy in patients with atrial fibrillation and chronic kidney disease: a nationwide observational cohort study. J Am Coll Cardiol 2014;64:2471-2482. https://doi.org/10.1016/j.jacc.2014.09.051
  147. Hylek EM, D'Antonio J, Evans-Molina C, Shea C, Henault LE, Regan S. Translating the results of randomized trials into clinical practice: the challenge of warfarin candidacy among hospitalized elderly patients with atrial fibrillation. Stroke 2006;37:1075-1080. https://doi.org/10.1161/01.STR.0000209239.71702.ce
  148. Sharma M, Cornelius VR, Patel JP, Davies JG, Molokhia M. Efficacy and harms of direct oral anticoagulants in the elderly for stroke prevention in atrial fibrillation and secondary preventionof venous thromboembolism: systematic review and meta-analysis. Circulation 2015;132:194-204. https://doi.org/10.1161/CIRCULATIONAHA.114.013267
  149. Mant J, Hobbs FD, Fletcher K, et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet 2007;370:493-503. https://doi.org/10.1016/S0140-6736(07)61233-1
  150. Gage BF, Birman-Deych E, Kerzner R, Radford MJ, Nilasena DS, Rich MW. Incidence of intracranial hemorrhage in patients with atrial fibrillation who are prone to fall. Am J Med 2005;118:612-617. https://doi.org/10.1016/j.amjmed.2005.02.022
  151. Halvorsen S, Atar D, Yang H, et al. Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial. Eur Heart J 2014;35:1864-1872. https://doi.org/10.1093/eurheartj/ehu046
  152. Investigators O, Yusuf S, Teo KK, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358:1547-1559. https://doi.org/10.1056/NEJMoa0801317
  153. Rao MP, Halvorsen S, Wojdyla D, et al. Blood pressure control and risk of stroke or systemic embolism in patients with atrial fibrillation: results from the apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (ARISTOTLE) trial. J Am Heart Assoc 2015;4:e002015. https://doi.org/10.1161/JAHA.115.002015
  154. Nagarakanti R, Wallentin L, Noack H, et al. Comparison of characteristics and outcomes of dabigatran versus warfarin in hypertensive patients with atrial fibrillation (from the RE-LY Trial). Am J Cardiol 2015;116:1204-1209. https://doi.org/10.1016/j.amjcard.2015.07.032
  155. Matsumoto M, Hori M, Tanahashi N, et al. Rivaroxaban versus warfarin in Japanese patients with non-valvular atrial fibrillation in relation to hypertension: a subgroup analysis of the J-ROCKET AF trial. Hypertens Res 2014;37:457-462. https://doi.org/10.1038/hr.2014.1
  156. Potpara TS, Lane DA, Lip GY. Optimizing stroke prevention in atrial fibrillation: better adherence and compliance from patients and physicians leads to better outcomes. Europace 2015;17:507-508. https://doi.org/10.1093/europace/euv041
  157. Kneeland PP, Fang MC. Current issues in patient adherence and persistence: focus on anticoagulants for the treatment and prevention of thromboembolism. Patient Prefer Adherence 2010;4:51-60.
  158. Rodriguez RA, Carrier M, Wells PS. Non-adherence to new oral anticoagulants: a reason for concern during long-term anticoagulation? J Thromb Haemost 2013;11:390-394. https://doi.org/10.1111/jth.12086
  159. Gorst-Rasmussen A, Skjoth F, Larsen TB, Rasmussen LH, Lip GY, Lane DA. Dabigatran adherence in atrial fibrillation patients during the first year after diagnosis: a nationwide cohort study. J Thromb Haemost 2015;13:495-504. https://doi.org/10.1111/jth.12845
  160. Shore S, Carey EP, Turakhia MP, et al. Adherence to dabigatran therapy and longitudinal patient outcomes: insights from the veterans health administration. Am Heart J 2014;167:810-817. https://doi.org/10.1016/j.ahj.2014.03.023
  161. Tsai K, Erickson SC, Yang J, Harada AS, Solow BK, Lew HC. Adherence, persistence, and switching patterns of dabigatran etexilate. Am J Manag Care 2013;19:e325-e332.
  162. Zalesak M,Siu K, Francis K, et al. Higher persistence in newly diagnosed nonvalvular atrial fibrillation patients treated with dabigatran versus warfarin. Circ Cardiovasc Qual Outcomes 2013;6:567-574. https://doi.org/10.1161/CIRCOUTCOMES.113.000192
  163. Schulman S, Shortt B, Robinson M, Eikelboom JW. Adherence to anticoagulant treatment with dabigatran in a real-world setting. J Thromb Haemost 2013;11:1295-1299. https://doi.org/10.1111/jth.12241
  164. Beyer-Westendorf J, Forster K, Ebertz F, et al. Drug persistence with rivaroxaban therapy in atrial fibrillation patients- results from the Dresden non-interventional oral anticoagulation registry. Europace 2015;17:530-538. https://doi.org/10.1093/europace/euu319
  165. Srivastava K, Arora A, Kataria A, Cappelleri JC, Sadosky A, Peterson AM. Impact of reducing dosing frequency on adherence to oral therapies: a literature review and metaanalysis. Patient Prefer Adherence 2013;7:419-434.
  166. Vrijens B, Heidbuchel H. Non-vitamin K antagonist oral anticoagulants: considerations on once- vs. twice-daily regimens and their potential impact on medication adherence. Europace 2015;17:514-523. https://doi.org/10.1093/europace/euu311
  167. Laliberte F, Nelson WW, Lefebvre P, Schein JR, Rondeau- Leclaire J, Duh MS. Impact of daily dosing frequency on adherence to chronic medications among nonvalvular atrial fibrillation patients. Adv Ther 2012;29:675-690. https://doi.org/10.1007/s12325-012-0040-x
  168. Gage BF, Yan Y, Milligan PE, et al. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J 2006;151:713-719. https://doi.org/10.1016/j.ahj.2005.04.017
  169. Rash A, Downes T, Portner R, Yeo WW, Morgan N, Channer KS. A randomised controlled trial of warfarin versus aspirin for stroke prevention in octogenarians with atrial fibrillation (WASPO). Age Ageing 2007;36:151-156. https://doi.org/10.1093/ageing/afl129
  170. Akins PT, Feldman HA, Zoble RG, et al. Secondary stroke prevention with ximelagatran versus warfarin in patients with atrial fibrillation: pooled analysis of SPORTIF III and V clinical trials. Stroke 2007;38:874-880. https://doi.org/10.1161/01.STR.0000258004.64840.0b
  171. Go AS, Hylek EM, Borowsky LH, Phillips KA, Selby JV, Singer DE. Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Ann Intern Med 1999;131:927-934.
  172. Delgado MG, Seijo S, Yepes I, et al. Efficacy and safety of anticoagulation on patients with cirrhosis and portal vein thrombosis. Clin Gastroenterol Hepatol 2012;10:776-783. https://doi.org/10.1016/j.cgh.2012.01.012
  173. Rodriguez-Castro KI, Simioni P, Burra P, Senzolo M. Anticoagulation for the treatment of thrombotic complications in patients with cirrhosis. Liver Int 2012;32:1465-1476. https://doi.org/10.1111/j.1478-3231.2012.02839.x
  174. Decousus H, Tapson VF, Bergmann JF, et al. Factors at admission associated with bleeding risk in medical patients: findings from the IMPROVE investigators. Chest 2011;139:69-79. https://doi.org/10.1378/chest.09-3081
  175. Lee SJ, Uhm JS, Kim JY, Pak HN, Lee MH, Joung B. The safety and efficacy of vitamin K antagonist in patients with atrial fibrillation and liver cirrhosis. Int J Cardiol 2015;180:185-191. https://doi.org/10.1016/j.ijcard.2014.11.183
  176. Stangier J, Stahle H, Rathgen K, Roth W, Shakeri-Nejad K. Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, are not affected by moderate hepatic impairment.J Clin Pharmacol 2008;48:1411-1419. https://doi.org/10.1177/0091270008324179
  177. Potze W, Arshad F, Adelmeijer J, et al. Differential in vitro inhibition of thrombin generation by anticoagulant drugs in plasma from patients with cirrhosis. PLoS One 2014;9: e88390. https://doi.org/10.1371/journal.pone.0088390
  178. Intagliata NM, Henry ZH, Maitland H, et al. Direct Oral Anticoagulants in Cirrhosis Patients Pose Similar Risks of Bleeding When Compared to Traditional Anticoagulation. Dig Dis Sci 2016;61:1721-1727. https://doi.org/10.1007/s10620-015-4012-2
  179. Joung B. Real-world data and recommended dosage of non-vitamin K Oral anticoagulants for Korean patients. Korean Circ J 2017;47:833-841. https://doi.org/10.4070/kcj.2017.0158

피인용 문헌

  1. 2018 KHRS Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Korean Patients with Atrial Fibrillation: How to Initiate and Organize the Follow-up vol.94, pp.1, 2018, https://doi.org/10.3904/kjm.2019.94.1.17
  2. Guideline of atrial fibrillation management vol.62, pp.5, 2019, https://doi.org/10.5124/jkma.2019.62.5.265
  3. Korean Heart Rhythm Society 2019 Practical Guidelines on Antithrombotic Therapy for AF Patients Undergoing Percutaneous Coronary Intervention or Structural Heart Disease Intervention vol.94, pp.4, 2019, https://doi.org/10.3904/kjm.2019.94.4.330
  4. What is Standard Dose of Rivaroxaban in Elderly Asian Patients with Atrial Fibrillation: 20ms versus. 15mg? vol.27, pp.None, 2018, https://doi.org/10.1177/10760296211061148
  5. Factors Influencing the Selection of Non-Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention in Patients With Non-Valvular Atrial Fibrillation vol.26, pp.6, 2021, https://doi.org/10.1177/10742484211049919